Variable
|
FRA positive
|
FRA negative
|
Total
|
P valueb
|
---|
|
N (%)
|
N (%)
| | |
---|
Marker
| | | | |
ER/PR(+)
|
3 (14%)
|
20 (86%)
|
23
| |
ER/PR/Her2(−)
|
19 (50%)
|
19 (50%)
|
38
|
0.0054
|
| | | |
[ER/PR(+) vs ER/PR/Her2(-)]
|
Tumor Grade
| | | | |
Grade 1
|
3 (30%)
|
7 (70%)
|
10
| |
Grade 2
|
11 (28%)
|
28 (72%)
|
39
|
1.0
|
| | | |
(Grade 1 vs Grade 2)
|
Grade 3
|
8 (67%)
|
4 (33%)
|
12
|
0.037
|
| | | |
(Grade 1 or 2 vs Grade 3)
|
Total Samples
|
22 (36%)
|
39 (64%)
|
61
| |
- FRA folate receptor alpha, Her2 human epidermal growth factor receptor type 2, ER estrogen receptor, PR progesterone receptor.
- a All samples were whole tissue FFPE (formalin-fixed, paraffin-embedded) slides.
- b P values calculated via 2X2 contingency table analysis using Fisher’s exact test.